CR
Cronos Group Inc.
CRON · NASDAQ
$3.16 -0.63% (-$0.02)
1M +3.57%
Market Cap $1.18B
P/E Ratio 16.89x
Div. Yield -
ROE 6.46%
Bulios Fair Price
$2.71
14.1% downside
Current Price
$3.16
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CRON is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
45 /100
Fair P/B 1.10x
P/S 4.85x
P/E 16.89x
Growth
82 /100
Growing Book val. growth 1.48%
Rev. growth 30.63%
FCF growth N/A
Profitability
69 /100
Strong FCF margin 18.34%
Op. margin 5.12%
Gross margin 33.54%
Quality
20 /100
Poor Asset turnover 0.21x
ROA 5.91%
ROIC 1.28%
Debt
100 /100
Low Current ratio 16.18x
Net debt/EBITDA -19.12x
Debt/Equity 0.00x
Stability
23 /100
Unstable Profitable years 0
EPS volatility 141.97%
Beta 1.24x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CRON
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Michael Ryan Gorenstein
Employees
610
Headquarters
Stayner
Upcoming events
05 NOV
Earnings
Upcoming earnings report